These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 9145428)
21. Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1. Lutz EM; MacKenzie CJ; Morrow J; Mitchell R; Bennie J; Carroll S; Clark E; Harmar AJ Ann N Y Acad Sci; 1996 Dec; 805():574-8. PubMed ID: 8993442 [No Abstract] [Full Text] [Related]
22. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor. Delporte C; Poloczek P; de Neef P; Vertongen P; Ciccarelli E; Svoboda M; Herchuelz A; Winand J; Robberecht P Mol Cell Endocrinol; 1995 Jan; 107(1):71-6. PubMed ID: 7796937 [TBL] [Abstract][Full Text] [Related]
23. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Akesson L; Ahrén B; Edgren G; Degerman E Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088 [TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro. Reed HE; Meyer-Spasche A; Cutler DJ; Coen CW; Piggins HD Eur J Neurosci; 2001 Feb; 13(4):839-43. PubMed ID: 11207820 [TBL] [Abstract][Full Text] [Related]
25. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. Nicole P; Du K; Couvineau A; Laburthe M J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823 [TBL] [Abstract][Full Text] [Related]
26. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389 [TBL] [Abstract][Full Text] [Related]
27. PACAP acts through VIP type 2 receptors in the rat testis. Krempels K; Usdin TB; Harta G; Mezey E Neuropeptides; 1995 Dec; 29(6):315-20. PubMed ID: 8837957 [TBL] [Abstract][Full Text] [Related]
28. Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion. Nogi H; Hashimoto H; Hagihara N; Shimada S; Yamamoto K; Matsuda T; Tohyama M; Baba A Neurosci Lett; 1997 May; 227(1):37-40. PubMed ID: 9178853 [TBL] [Abstract][Full Text] [Related]
30. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Svoboda M; Tastenoy M; Van Rampelbergh J; Goossens JF; De Neef P; Waelbroeck M; Robberecht P Biochem Biophys Res Commun; 1994 Dec; 205(3):1617-24. PubMed ID: 7811244 [TBL] [Abstract][Full Text] [Related]
31. Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle. Ekblad E; Sundler F Eur J Pharmacol; 1997 Sep; 334(1):61-6. PubMed ID: 9346329 [TBL] [Abstract][Full Text] [Related]
32. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304 [TBL] [Abstract][Full Text] [Related]
33. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883 [TBL] [Abstract][Full Text] [Related]
34. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons. Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697 [TBL] [Abstract][Full Text] [Related]
35. Role of VIP1/PACAP receptors in postoperative ileus in rats. De Winter BY; Robberecht P; Boeckxstaens GE; De Man JG; Moreels TG; Herman AG; Pelckmans PA Br J Pharmacol; 1998 Jul; 124(6):1181-6. PubMed ID: 9720789 [TBL] [Abstract][Full Text] [Related]
36. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056 [TBL] [Abstract][Full Text] [Related]
37. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC. Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681 [TBL] [Abstract][Full Text] [Related]
38. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Schmidt DT; Rühlmann E; Waldeck B; Branscheid D; Luts A; Sundler F; Rabe KF Naunyn Schmiedebergs Arch Pharmacol; 2001 Oct; 364(4):314-20. PubMed ID: 11683518 [TBL] [Abstract][Full Text] [Related]
39. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors. Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281 [TBL] [Abstract][Full Text] [Related]
40. Differential alternative splicing of PACAP receptor in pituitary cell subpopulations. Vertongen P; Velkeniers B; Hooghe-Peters E; Robberecht P Mol Cell Endocrinol; 1995 Sep; 113(2):131-5. PubMed ID: 8674820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]